Literature DB >> 7440521

Rating depressive patients.

M Hamilton.   

Abstract

Various methods can be used for assessing symptoms of depression. These include check lists, scales for patient self-rating and rating scales completed by trained professional observers. Each technique has its special place in psychiatric research and each technique has its own strengths and weaknesses. A common concern on the part of psychiatrists is the fear that numerical assessment is dehumanizing. This is not the case as this method is intended only to make statistical analysis convenient and in no way reduces the concern for the subject's individuality. A commonly used depression rating scale, the Hamilton, has been extensively used in clinical trials of antidepressant drugs and for other purposes in clinical research. The various items of that scale are discussed and the system of rating explored from a clinician's point of view.

Entities:  

Mesh:

Year:  1980        PMID: 7440521

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  139 in total

1.  Pilot study of treatment for major depression among women prisoners with substance use disorder.

Authors:  Jennifer E Johnson; Caron Zlotnick
Journal:  J Psychiatr Res       Date:  2012-06-12       Impact factor: 4.791

2.  Telomere length is inversely correlated with urinary stress hormone levels in healthy controls but not in un-medicated depressed individuals-preliminary findings.

Authors:  Brittany Fair; Synthia H Mellon; Elissa S Epel; Jue Lin; Dóra Révész; Josine E Verhoeven; Brenda W Penninx; Victor I Reus; Rebecca Rosser; Christina M Hough; Laura Mahan; Heather M Burke; Elizabeth H Blackburn; Owen M Wolkowitz
Journal:  J Psychosom Res       Date:  2017-06-15       Impact factor: 3.006

3.  Data standards for clinical research data collection forms: current status and challenges.

Authors:  Rachel L Richesson; Prakash Nadkarni
Journal:  J Am Med Inform Assoc       Date:  2011-05-01       Impact factor: 4.497

4.  Differences between males and females in rates of serotonin synthesis in human brain.

Authors:  S Nishizawa; C Benkelfat; S N Young; M Leyton; S Mzengeza; C de Montigny; P Blier; M Diksic
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

5.  Midline Brain Abnormalities Across Psychotic and Mood Disorders.

Authors:  Ramón Landin-Romero; Benedikt L Amann; Salvador Sarró; Amalia Guerrero-Pedraza; Victor Vicens; Elena Rodriguez-Cano; Eduard Vieta; Raymond Salvador; Edith Pomarol-Clotet; Joaquim Radua
Journal:  Schizophr Bull       Date:  2015-07-17       Impact factor: 9.306

6.  Integrating Depression Care Management into Medicare Home Health Reduces Risk of 30- and 60-Day Hospitalization: The Depression Care for Patients at Home Cluster-Randomized Trial.

Authors:  Martha L Bruce; Matthew C Lohman; Rebecca L Greenberg; Yuhua Bao; Patrick J Raue
Journal:  J Am Geriatr Soc       Date:  2016-10-14       Impact factor: 5.562

7.  Ketamine induced changes in regional cerebral blood flow, interregional connectivity patterns, and glutamate metabolism.

Authors:  James Edward Bryant; Michael Frölich; Steve Tran; Meredith Amanda Reid; Adrienne Carol Lahti; Nina Vanessa Kraguljac
Journal:  J Psychiatr Res       Date:  2019-07-27       Impact factor: 4.791

8.  Assessment of cerebrovascular reactivity during major depression and after remission of disease.

Authors:  Alireza Vakilian; Farhad Iranmanesh
Journal:  Ann Indian Acad Neurol       Date:  2010-01       Impact factor: 1.383

9.  Suicidality, depression, major and minor negative life events: a mediator model.

Authors:  Jochen Hardt; Jeffrey G Johnson
Journal:  Psychosoc Med       Date:  2010-09-22

10.  Effectiveness of the psychological and pharmacological treatment of catastrophization in patients with fibromyalgia: a randomized controlled trial.

Authors:  Javier García-Campayo; Antoni Serrano-Blanco; Baltasar Rodero; Rosa Magallón; Marta Alda; Eva Andrés; Juan V Luciano; Yolanda López del Hoyo
Journal:  Trials       Date:  2009-04-23       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.